Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 02, 2026 07:05 ET | Source: TriVoca Health

Sago Health Announces Rebrand to TriVoca Health

Cranford, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sago Health today announced its rebrand as TriVoca Health, marking an evolution in the company’s mission to elevate the voices that shape healthcare...
February 02, 2026 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
February 02, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual...
February 02, 2026 07:00 ET | Source: Guidelight Health

Guidelight Expands to California with Opening of Los Angeles Clinic

Guidelight is proud to join the Los Angeles community. Our teams will serve people with mental health needs. For more info. go to guidelighthealth.com
February 02, 2026 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026...
February 02, 2026 06:50 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Product is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq:...
February 02, 2026 05:48 ET | Source: NUTRA HARMONY LLC

How Consumers Evaluate Mullein Extract Supplements and Drops in 2026: New Research from NUTRAHARMONY

NUTRAHARMONY has released a 2026 research-based consumer guide examining how consumers assess mullein extract supplements and drops.
February 02, 2026 03:00 ET | Source: Alvotech

Alvotech gerir samninga um markaðssetningu á fyrirhuguðum hliðstæðum í Kanada, Ástralíu og Nýja-Sjálandi

REYKJAVÍK (2. FEBRÚAR 2026) - Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að samningar hefðu náðst við svissneska lyfjafyrirtækið Sandoz, um sölu og markaðssetningu í Kanada, Ástralíu og...
February 02, 2026 03:00 ET | Source: Alvotech

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
February 02, 2026 03:00 ET | Source: Alvotech

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients...